Advertisement

TheBodyPRO.com covers IDWeek 2015

News

What's Hot in HIV Clinical Science

October 8, 2015

 1/5 

What's Hot in HIV Clinical Science

A lot has changed in the world of HIV clinical science since last year's IDWeek meeting. In the past year, groundbreaking clinical data have dramatically reshaped the way the medical community thinks about HIV treatment.

Some new revelations have been frustrating setbacks. For example, the relapse of the "Mississippi baby" made it clear that there is still more work to be done to disrupt latent reservoirs of HIV.

Yet other research has led to dramatic changes in treatment guidelines, such as the new World Health Organization (WHO) guidelines that now recommend antiretroviral treatment (ART) for all newly diagnosed patients, regardless of their CD4+ count.

During a keynote symposium at IDWeek 2015 in San Diego, California, Adaora Adimora, M.D., M.P.H., a professor of medicine and epidemiology at the University of North Carolina, offered a comprehensive look back at the last year of clinical science in HIV.

Get Started





This article was provided by TheBodyPRO.com. It is a part of the publication IDWeek 2015.
 


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.